effect of treatment, it has been recommended that SSA/SSB-positive women be referred for fetal echocardiography surveillance. The current standard screening (SS) protocol is weekly to bi-weekly fetal echocardiograms beginning in the early second trimester (16) (17) (18) weeks) until 28 weeks of gestation. 9 Many studies questioned the utility of the current practice as CHB largely develops without a "warning period" and screening may not lower the incidence of CHB as there is no proven effective treatment to prevent CHB. 8 
SS leads
to high cost and resource utilization in the fetal echocardiography laboratory. Alternative screening protocols have been suggested, including targeted screening for high risk population or limited screening (LS) approaches, acknowledging the limited data supporting the efficacy of fetal treatment.
14 Some of the factors that increase the risk of development of CHB include positive family history of CHB in previous pregnancies and high antibody levels. The risk increases to 15%-20% for those with a positive family history in a previous pregnancy with CHB. 8 Another high-risk group is patients with high antibody levels. In a recent study that risk stratified pregnancies according to the anti-Ro/SSA levels, no cases of conduction abnormalities were detected in pregnancies with an antibody level below 50 U/mL. On the other hand 8/127 (6%) of fetuses with levels above 50 U/mL developed conduction abnormalities and 3% had CHB. 4, 14 While it is unlikely the possibility of fetal conduction abnormalities in those pregnancies with an antibody level below 50 U/mL is zero, the rarity of events in this group has resulted in a change of the screening strategies of some centers to targeted screening that includes weekly SS only in pregnancies with high antibody levels. 4, 14 In this study, we sought to identify the strategy that optimizes resource utilization in screening for CHB to deliver high value prenatal care using decision analysis modeling techniques. The study compared the utility and cost-effectiveness of SS paradigm to an approach in which only those fetuses with high maternal antibody levels are closely monitored with weekly echocardiograms: "targeted screening by maternal antibody level" (TS). Finally, these two approaches were compared against a LS paradigm in which only one fetal echocardiogram is performed and routine obstetrical care is recommended if there is no evidence of conduction abnormalities.
| MATERIAL AND ME THODS
A decision analytic model ( Figure 1 ) was developed which simulated three treatment paradigms, whereby a pediatric cardiology provider may approach a pregnant woman with known positive autoantibodies using TreeAge Pro (Williamstown, Massachusetts). The SS paradigm modeled the current approach at our institution which adheres to American Heart Association recommendations for weekly PR F I G U R E 1 Cost-utility model. Abbreviation: HB, heart block interval screening between 16 and 28 weeks gestational age. 5 Under SS, if first or second degree heart block (other heart block, OHB) is detected, a steroid treatment of the mother is initiated in an attempt to prevent progression to CHB. The LS paradigm serves as the cost- 
| Cost assumptions
As is standard for cost-utility analyses, costs were defined as payer 
| Probability assumptions
Model inputs were derived from the existing literature (Table 1) . To allow for sensitivity analyses affecting all paradigms in tandem, all probabilities pertaining to OHB or CHB were a factor of a single incidence variable, "Fetal Heart Block (any degree)." Using the limited available data on the incidence of OHB, it was assumed that OHB would be twice as common as CHB in all models. 9 The assumptions were challenged with sensitivity analyses. We assumed the probability of fetal conduction abnormalities in those with antibody levels <50 U/mL to be rare, but non-zero. Because the efficacy of steroid therapy to prevent progression of AV block is controversial, a sensitivity analysis was performed to characterize the probability of treatment benefit. It was assumed in the LS and TS paradigms that after an initial reassuring fetal cardiology assessment, CHB would be identified through routine obstetrical screening by the discovery of bradycardia and receives treatment.
| Utility assumptions
For metrics of efficacy, quality-adjusted life years (QALY) from the infant's perspective were used. Utility values were extracted from the literature and where an appropriate utility value could not be found, an assumption was made for the baseline analysis and subsequently challenged with sensitivity analyses (Table 1 ). The incremental costeffectiveness ratio (ICER) was used to define cost-effectiveness with a willingness-to-pay (WTP) threshold of $50 000, acknowledging this is considered the lower boundary defining cost-effectiveness. 16 There was an assumed steroid-related neonatal reduced utility given the associated risk of prematurity and growth restriction. 
| Time assumptions
Life-expectancy was in accordance with updated Center for Disease Control estimates. 16 The length of time suffering the steroid-related sequelae described above was assumed to be 0.5 years. The length of neonatal hospitalization was averaged from our internal patient data.
| RE SULTS
Our internal database identified 77 pregnancies who had been followed using SS surveillance methodology. For these 77 pregnancies, an average of 7. Table 1 Two-way sensitivity analyses were performed upon several variable pairs highlighted in the tornado analysis. Focusing on the probabilities pertaining to progression of OHB to CHB, Figure 3 illustrates a two-way sensitivity analysis in which the probability of progression from OHB to CHB of an untreated fetus is varied against the degree to which steroid therapy reduces that risk of progression across the assumption ranges outlined in Table 1 . The figure graphically conveys that if the likelihood of progressing from untreated OHB to CHB in fetal life is less than 45.1% or if progressing despite treatment is greater than 27.5% (relative risk reduction of treatment less than 0.45), then LS will be the advised model. Similarly, Figure 4 is a two-way sensitivity analysis wherein the prevalence of conduction abnormalities in this population was varied against the efficacy of steroid treatment. The analysis shows that at the baseline assumed steroid efficacy of a 0.5 relative risk reduction, if the incidence of any degree of fetal conduction block was less than 2.7% the LS will be the advised model. The SS becomes cost effective if conduction abnormalities are more common than 15.6%. Additionally, a Monte Carlo was performed utilizing a hypothetical 10 000 patient cohort ( Figure 5 ). From this was extrapolated a cost-acceptability curve which illustrated that at a WTP of $50 000, TS was the cost-effective paradigm in 40% of the simulations with LS the advised paradigm in the reciprocal 59% (Figure 6 ). In only 1% of simulations was SS found to be cost-effective.
| D ISCUSS I ON
Maternal autoantibodies for anti-Ro/SSA and anti-LA/SSB are the most common cause of congenital CHB. 11 The current screening protocol used by many centers in North America (SS) results in high-cost and high-resource utilization while emerging data suggests targeted screening for pregnancies with high autoantibody levels. 4, 5 This study used our institutional experience and modeled the different screening strategies for fetal conduction abnormalities. The findings revealed that the current SS approach is not cost-effective and that the new emerging strategy of TS using the antibody level of maternal antibodies is a cost-effective alternative strategy in this population.
The SS includes weekly or bi-weekly visits with fetal echocardiograms. This approach has the highest QALY in our study as it was thought to detect and treat conduction abnormalities across the study population whereas the TS approach allowed rare conduction abnormalities to progress to CHB without treatment in the <50 U/mL group. 9 However, in the PRIDE study that included 98 pregnancies, 3 fetuses developed CHB and none had preceding conduction abnormalities. 9 Significant assumption changes would be required in order to conclude SS would be cost-effective; for conditions in which the clinician feels the prevalence of conduction abnormalities are more common than 15.6%, as may be the case in which a prior sibling of that fetus had experienced CHB prenatally, our analysis would support a SS approach (Figure 4 ). 4 Furthermore, the model did not take into consideration the effects of SS on the mothers including inconvenience, anxiety, and the indirect costs of work days missed because of the frequent visits which makes this strategy even less appealing and less practical as a universal approach.
The antibody levels are now clinically and commercially available. 4 Kan et al, reviewed their experience with risk stratification using maternal antibody levels. Their screening strategy was similar to the TS proposed in our study. Their study proved the safety of the TS strategy as no cases of complete or incomplete heart block developed in pregnancies with antibody levels less than 50 U/mL over a 5 year period among the 189 screened fetuses. 4 Their study showed a prevalence of high titers of about 20% which resulted in about 80%
decrease in utilization of fetal echocardiograms. Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years.
TA B L E 2 Cost-utility analysis results

Cost-effectiveness analysis results
Paradigm
F I G U R E 2 Cost-utility baseline results. Abbreviation: QALY, quality-adjusted life years F I G U R E 3 Two-way sensitivity analysis varying the probability of progression of untreated first or second degree heart block to third degree heart block and the efficacy of treating first or second degree heart block at preventing progression to third degree. Baseline assumptions (---). Abbreviations: CHB, complete heart block; OHB, other heart block The sensitivity analyses illustrate boundary conditions for the model conclusions. As indicated in Figures 3 and 4 , the base case assumptions are near boundary conditions for three of the more controversial variables: "untreated first or second degree, progressing,"
"treated first or second degree, progressing," and "fetal heart block (any degree)." Therefore, variations in reader assumptions regarding these values can affect the conclusion of this analysis. However, if any variations in these assumptions change the conclusion, as Figures   3 and 4 indicate, this would advocate for LS over either alternative.
The variable that seems to have the most effect on the model is the efficacy of the steroid treatment. While some studies advocate for treatment with steroids for OHB, recent studies challenge the efficacy of steroids. 4 In our analysis, we assumed that steroids prevent the progression of OHB to CHB in 50% of the cases which would otherwise have progressed, with 25% progression in untreated cases based on the results of the PRIDE study. 9, 10 If steroid efficacy is much less than 50% that will advocate for LS strategy. As the actual efficacy of steroids is yet to be determined, TS may be a F I G U R E 4 Two-way sensitivity analysis varying the probability of a conduction abnormality (any degree) in utero and the efficacy of treating first or second degree heart block at preventing progression to third degree. Baseline assumptions (---)
F I G U R E 5 Monte Carlo. Abbreviation: QALY, quality-adjusted life years reasonable alternative to the SS strategy that optimizes resource utilization compared to the current SS. Finally, our sensitivity analyses have shown our model conclusion to be insensitive to LS prenatal costs; if an obstetrics group were to increase their fetal heart rate surveillance frequency in response to a TS or LS approach by the pediatric cardiologist or add an ambulatory fetal heart rate surveillance program, 17 our recommendations remain the same as it will take a very significant increase in the prenatal cost of LS or TS to make SS justified.
Given that mortality and the lifelong need for a pacemaker is extremely uncommon in these models, the QALY difference between surveillance approaches is small. The Monte Carlo analysis in Figure 5 illustrates that the range of QALYs experienced by these infants is concentrated and maximized in the SS approach while the variation in QALYs experienced is widest in LS, including a few simulations with QALYs below 77.5. However, our analysis would indicate that the avoidance of these low QALY outcomes by pursuit of SS is not cost-effective. Figure 5 illustrates that TS achieves near-as concentrated a QALY distribution as SS, yet for less cost in all but a few cases.
| LI M ITATI O N S
Our center receives referrals of fetuses in known heart block for consideration of future pacemaker placement, so our data cannot be used for derivation of incidence values. All of the cost and hospitalization data is from our institution only, thus cost analysis did not include the cost of stay at an outside hospital or the cost of transfer to our institution. Also, some newborns had complications unrelated to CHB and thus excluded from the analysis not to exaggerate the cost of neonatal admission in cases of CHB. Furthermore, this model assumes that bradycardia will be detected by the obstetricians and will trigger referral back to cardiology. Finally, the effect of steroid treatment to prevent the progression to CHB is not well known and thus, was addressed using sensitivity analysis.
| CON CLUS ION
While the efficacy of fetal intervention for first or second degree AV block remains unclear, given the morbidity implications of CHB, the current recommendations advocate for fetal surveillance efforts. Our analysis proves that the current commonly used SS strategy is not cost-effective except in situations in which the prevalence of disease is elevated, as would be the case for a woman with a prior affected fetus. However, a targeted screening strategy using maternal antibody levels is a cost-effective alternative strategy.
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